Barinthus Biotherapeutics Financials - Benzinga

Barinthus Biotherapeutics PLC

BRNSNASDAQ

Trade with Public

Trade with Public

$0.7590

0.03965.5%

At close: Sep 4, 5:00 PM EST

$0.7600

0.0010.13%

After Hours: Sep 4, 4:49 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Compare Stock Report

Barinthus Biotherapeutics Financials

Barinthus Biotherapeutics (BRNS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Barinthus Biotherapeutics Q2 EPS $(0.26) Beats $(0.30) Estimate

Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 50 percent increase over losses of $(0.52) per

Benzinga Newsdesk

PRO
Barinthus Biotherapeutics Q1 EPS $(0.14) Beats $(0.30) Estimate

Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.30) by 53.33 percent. This is a 71.43 percent increase over losses of $(0.49) per

Benzinga Newsdesk

PRO
Barinthus Biotherapeutics Q4 EPS $(0.27) Beats $(0.40) Estimate

Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.40) by 32.5 percent. This is a 47.06 percent increase over losses of $(0.51) per

Benzinga Newsdesk

PRO
Barinthus Biotherapeutics Q3 EPS $(0.36) Beats $(0.45) Estimate, Sales $14.969M, Same YoY

Benzinga Newsdesk

PRO
Barinthus Biotherapeutics Q2 EPS $(0.52) Misses $(0.33) Estimate

Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.33) by 57.58 percent. This is a 20.93 percent decrease over losses of $(0.43) per

Benzinga Newsdesk

PRO
Barinthus Biotherapeutics Q1 EPS $(0.49) Misses $(0.36) Estimate

Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.36) by 36.11 percent. This is a 22.5 percent decrease over losses of $(0.40) per

Benzinga Newsdesk